Research

Researchers Develop Marburg Virus Treatment Effective Five Days After Infection

Virus causes hemorrhagic fever often leading to death


By Donna Ramirez | April 07, 2017

An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.

There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.

Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.

“In this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus-infected non-human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus,” said UTMB’s Thomas Geisbert, professor in the department of microbiology and immunology. “These findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic.”

The study was conducted in Biosafety Level (BSL)-4 at UTMB’s Galveston National Laboratory. BSL-4 is a highly-restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL-4 laboratory located on an American university campus.

The 2013 to 2016 Ebola virus epidemic highlighted the troubling lack of preventive or treatment options for filoviruses. Some of the therapeutics used to treat those infected with Ebola were developed and tested in the GNL.

“The level of protection observed by Dr. Geisbert’s team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible,” said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.

Other authors of this paper include UTMB’s Chad Mire, Joan Geisbert, Viktoriya Borisevich, Karla Fenton, Krystle Agans and Daniel Deer; Andrew Flyak and James Crowe, Jr. from Vanderbilt University Medical Center; Herta Steinkellner from the University of Natural Resources and Life Sciences in Vienna and Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do Kim, Michael Pauly, Jesus Velasco and Kevin Whaley.

This study was supported by the Department of Health and Human Services, National Institutes of Health and BSL-4 operations support of the Galveston National Laboratory.

Tags | Research



Social Posts

profile_image

BCMHouston

@bcmhouston

RT @BCMHouston_News: Congratulations to @bcmhouston's Dr. Meng Wang, a 2018 #HHMIInvestigator! She is making dramatic advances in how we un…

23 mins ago
profile_image

San José Clinic

SanJoseClinic

Thank you to the Houston Hispanic Dental Association for volunteering your time and talents at our latest Saturday Clinic! Your generosity and partnership help us make smiles together.

27 mins ago
profile_image

BCMHouston

@bcmhouston

School of Medicine graduating student Aishwarya Venkataraman shares her unique connection she formed with Baylor College of Medicine at a young age. https://t.co/Sa1C7LNXBg

34 mins ago
profile_image

Rice University

@RiceUniversity

Despite the economic and political stakes, debate on how to value groundwater in Texas has been sparse, according to an expert from the @CES_Baker_Inst. https://t.co/DeMZL5BWQG https://t.co/yLwNZxTWkd

34 mins ago
profile_image

Baylor College of Medicine

BaylorCollegeOfMedicine

Glow from the inside out with these foods for radiant skin.

34 mins ago
profile_image

UTMB Health

@utmbhealth

RT @erikafuchs: Head to the women’s health poster session today at 2 PM in the Levin Hall dining room. @utmbhealth @CIRWH @utmbnews https:/…

36 mins ago
profile_image

Veterans Affairs

@DeptVetAffairs

#VAntagePoint: VA doctor survives stroke with help of VA TeleStroke program he helped put in place https://t.co/ufEqhnYjXl

48 mins ago
profile_image

University of Houston

@UHouston

Live now! https://t.co/hq70sDkWZR

52 mins ago
profile_image

UTMB Health

@utmbhealth

RT @utmbnews: Patient condition updates 5/23/18 9:00 a.m. Adult male remains in CRITICAL condition and adult female remains in GOOD conditi…

59 mins ago
profile_image

Texas Children's

@TexasChildrens

In Legacy Tower shell space was created as a designated area on every floor to store additional beds. https://t.co/KsI2f8lvtO

1 hour ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

MD Anderson president @PPisters on what lies ahead: "We have the opportunity to create a totally different environment for patients, game-changing in the industry." https://t.co/Gd18pzpP68 @HoustonChron #endcancer

1 hour ago
profile_image

University of Houston

@UHouston

RT @American_BSB: Fans - we have live streams going at both fields today. Or you can hop between them at https://t.co/MsmsWQjewg… @GoShock…

1 hour ago
profile_image

University of Houston

@UHouston

RT @UHVetServices: Welcome new CoogVets! 😁🐾🇺🇸 https://t.co/fB7oOjys7k

1 hour ago
profile_image

BCMHouston

@bcmhouston

RT @dana_fdn: Join @NYASciences for the #RossPrize2018 presentation and lecture on June 5th, honoring @bcmhouston @HHMINEWS’s Dr. Huda Y. Z…

1 hour ago
profile_image

Rice University

@RiceUniversity

https://t.co/McLohcR8cS

2 hours ago